Q is Phen/topira. Phen has been around for a long time as well as Topira but the combination is what makes it most effective and patentable. When Fen/Phen were combined and marketed in the 90s as Pondimin a huge lawsuit resulted in over $13B due to heart/pulmonary issues and the drug was yanked. Phen and Topira both serve different functions and it's proven safe. Both drugs alone can have serious adverse effects therefore it is a controlled substance and must be approved by the FDA. Qs patent is as good as gold hence Teva wants it badly. Q's issue is marketing/sales in quicker fashion. Teva can buy Q out and pay royalties. Denner, BOD and I would like that.....and special dividends of $1/cash per share a few times a year.
I agree. Now that the initial quarter has produced and operations has a benchmark to measure from, MNKD will start to double sales volume every quarter or two until it reaches $1B in sales within a few years. Blockbuster drug....yes indeed!
Every dog has its day and this was a great short for you if what you say is true (I doubt it since I employ the assume rule). Now the tide has turned as it should have. I shouldn't feel too bad as my buy in price was in the low to mid 2s. But I play to win and this stock will now rise as the spirits have risen the upper hand. You'd best cover lest you give back your 'profits' bonehead butt boy. Don't say that I didn't warn ya and also that they charge a lot of interest on those borrowed shares on top of any loss.
Told ya so!
Seth going on the tightrope to say that Vivus can be neutral or profitable by end of next year is cautiously optimistic. Knowing the BOD, they can all agree that the strategy is correct therefore there will be no change in upper management and the Fund directors can be confident that they will get back their investment along with profits starting with the next two quarters. This will be the first time in Vivus history, also 22 years as a publicly traded company, that Vivus will start showing its true worth. This could be a stock worth $50 next year. Grand slam.....stock up now!
done in the past. I wouldn't doubt that this company becomes a cash cow with dividends, or the highly sought after special dividends, beginning next year. This is a nice hedge strategy leading to super growth or a solid acquisition. Stock price will pop to over $2 tomorrow.
Yes, usually a good sign that the company will be profitable by 3rd quarter in 2016 and will be a takeout target.
That's because Al Mann laughed in all of the manipulator faces. He's a lot like Donald Trump....he speaks his mind and nobody can manipulate him. Lil Adam Farrstain is as Ugly as they come. He likes to smoke his Exubera bong with his boyfriend as they call each other Losers!
Because MikeAnthony is a loser creep who boasts how much money he made on ITEK right before it shot up and burned his short behind. Later you loser.....Mikey boy
Who is the bond holder that you are referring to and how much of the debt is secured in the covenant? I'm only getting half of your picture.
That's a very good question; my hat is off to you. Enzon will continue to receive immunity fees on actively marketed products, after the expiration of patents and royalties, for a period of 12 years. Therefore the teats will continue to produce milk for quite some time.
I anticipate hearing some updates on the Belrose trials by the end of the year which could benefit the ENZN shareholders tremendously. Couple that with the NOL's and the company will be in great shape to be acquired. Until then the sweet special dividends will just keep rolling in. This is a great stock to sleep on at night.
What do you think of the Belrose relationship outside of the sweet deal they received?
That's an interesting thought. They haven't been able to find a worthwhile buyer and they are slow to market on the partnerships. I doubt seeing the company going private but maybe some special dividends are paid out to make a buyout deal more attractive. This stock is so oversold so something has to come from this upcoming conference to rebuild the confidence.
He likes the refillable bong and the quick action time so he can get it on before writing his gobbly #$%$ articles.
Good points cwn. The special ruling applies for dividends over 25% of the stock price thereby giving time for all of the credit and paperwork to be filed and processed. The fifty cent dividend qualified for the special ruling. Some played the pop pretty well off of the fools ignorance. I will remember this on the next dividend event.
He's in his mid sixties and just learned of his diabetes illness last year. He said to a group of us that he had to eat candy bars to help regulate his sugar level and that he is tired of poking himself with needles. I asked him if he'd heard of Afrezza and he said that he did not. He said that his doctor didn't mention it during his visits. He said that Afrezza sounded much more convenient and painless than his current injections and will ask his doctor for advice on getting prescribed. He thanked me for bringing it up as it obviously bothers him a lot (on top of his diabetes). All of the others in the group were really listening to the conversation and didn't respond so they obviously were catching word of something new. Hopefully more of this word will get out as people start discussing Afrezza more.